Summary of Key Points from Conference Call Records Industry Overview - The conference call primarily discusses the **pet food industry** and its growth prospects, highlighting the rise of domestic brands and their market dynamics [2][3]. Core Insights and Arguments 1. **Growth of Domestic Pet Food Brands**: The domestic pet food market is expected to see online sales growth of **30%-40%** in 2025, driven by import tariffs and brand operational advantages, benefiting leading brands like **Guibao Pet** [2][3]. 2. **Guibao Pet's Performance**: Guibao Pet is noted for its product iteration and online operational capabilities, with a projected scale of **840 million to 1.12 billion** RMB in 2025, corresponding to a **50x PE ratio** this year and **40x** next year, suggesting a strong investment opportunity [2][3]. 3. **Zhongchong Co.'s Profitability**: Zhongchong Co. is expected to see profit contributions from exports increase, with projected earnings of **440 million** RMB in 2025 and **850 million** in 2026, also recommending aggressive investment [2][3]. 4. **Ruip Bio's Full Industry Chain Layout**: Ruip Bio is highlighted for its comprehensive industry chain layout, with expected main business profits of **450 million to 570 million** RMB and a valuation of about **25x PE**, making it a key focus for investors [2][3]. 5. **Miniso's International Growth**: Miniso reported strong overseas growth of **30%** in Q1, although domestic same-store sales declined, impacting profitability. The company is entering a performance inflection point, still considered a valuable investment [2][4]. 6. **Automotive Industry Price War**: The automotive sector is experiencing a price war, with companies like **BYD** increasing terminal discounts to stimulate sales. New car launches in June are expected to drive demand, potentially squeezing market share from joint venture brands [2][9][10]. 7. **CXO Sector Recovery**: The CXO sector is benefiting from a recovery in overseas biopharmaceutical investment, with significant growth in new orders for CDMO companies. Leading firms like **WuXi AppTec** are seen as undervalued, presenting substantial investment opportunities [2][24][25]. Additional Important Insights - The pet industry is characterized by a high level of consumer interest and a scarcity of competitive tracks, enhancing valuation potential [3]. - The shift towards domestic brands is accelerated by foreign brands raising prices due to tariffs, favoring high-end domestic brands [3]. - The automotive price war is expected to continue affecting market dynamics, with domestic brands likely to gain further market share at the expense of joint ventures [9][10]. - The CXO sector's growth is closely tied to pharmaceutical R&D investments, with a notable recovery in order volumes indicating a positive outlook for the industry [24][25]. This summary encapsulates the key points discussed in the conference call, focusing on the pet food industry, automotive sector dynamics, and the recovery in the CXO space, providing a comprehensive overview for potential investors.

Group 1 - The overall market experienced a decline in the afternoon, but the pharmaceutical and medical sectors showed resilience, with only three out of 31 industries reporting gains [1] - The representative medical ETF (512170) saw a daily increase of 0.62%, with a significant trading volume of 9.82 billion, marking a 128% increase from the previous day and the highest single-day trading volume in over a month and a half [2] - The CXO-related stocks were the main contributors to the sector's performance, with notable gains from companies like Tigermed, which rose by 5.64%, while major player WuXi AppTec experienced a decline [2] Group 2 - For the week of May 19-23, the medical ETF (512170) accumulated a gain of 1.24%, outperforming major indices such as the Shanghai Composite Index, which fell by 0.57% [4] - The market for medical stocks is gradually recovering, with increased trading activity and positive catalysts such as domestic pharmaceutical companies securing overseas contracts [4] - A new "Pharmaceutical ETF" is set to launch on May 26, which will track the CSI Pharmaceutical Index, focusing on chemical drugs, biological drugs, and traditional Chinese medicine, complementing the existing medical ETF [4] Group 3 - The medical and pharmaceutical sectors have been in a prolonged adjustment period since 2021, with current valuations potentially offering high cost-effectiveness for investors [4]

Core Insights - The uncertainty surrounding U.S. tariffs on pharmaceuticals is impacting the global pharmaceutical sector, but the overall effect on China's pharmaceutical industry is expected to be limited [1][2] - Chinese CXO (Contract Research Organization) companies are becoming increasingly significant in the global supply chain, but the impact of tariffs will primarily be felt by their clients, leading to increased supply costs [2] - The rise of innovative drugs in China is notable, particularly in the Hong Kong market, where clinical-stage products are being evaluated based on their potential global market performance [2][3] Impact of Tariffs - The potential tariffs are likely to have a limited impact on China's pharmaceutical industry, especially for finished drugs, as the export volume is relatively small [1] - For medical device companies, the exposure to the U.S. market is also limited, with many products targeting emerging markets instead [1] - Companies with exposure to the U.S. market may prioritize depleting their existing inventory in the U.S. in response to tariff uncertainties [1] CXO Industry Dynamics - Most tariff costs will be borne by clients of CXO companies, which may lead to increased supply chain costs [2] - The process of reshoring manufacturing to the U.S. is complex and time-consuming, requiring 2-3 years for new facilities and additional time for regulatory approvals [2] - The talent pool necessary for replicating China's CDMO success is difficult to establish in the U.S. and Europe, making it challenging to recreate the same level of global influence [2] Innovative Drug Market - The evaluation of clinical-stage products is based on their projected peak sales and market penetration, which has become more familiar to investors since the opening of the Hong Kong market to unprofitable biotech firms [2] - Chinese innovative drugs are gaining global recognition, leading to increased investor interest as companies begin to license products internationally [2][3] - The competitive landscape for Chinese innovative drugs is still developing, with further observation needed over the next 3-5 years to assess their commercial viability against global competitors [3][4] Future Disease Areas - Oncology remains a significant area of exploration, with continued opportunities for growth [4] - Other promising fields include autoimmune diseases, metabolic disorders, and neurodegenerative diseases [4]

热点板块：5月可重新关注科技成长及创新药。低估值、高股息方向在4月跑出超额收益属于历史规 律，进入5月后市场风格有可能重新切换回科技成长。除了业绩落地之外，5月科技方向可以期待的催化 剂包括AI大模型版本的更新，以及机器人格斗大赛等，预计科技成长将迎来反弹。关注：1）英伟达 GTC大会确认AI发展从模型训练进入推理阶段，关注衍生的AI新方向，如云计算、AI+办公、AI+医药 等。5月关注AI大模型的版本更新。2）机器人国产化和走进老百姓生活依然是2025年比较确定的趋 势，机器人产品将从人形机器人向四足机器人、功能型机器人扩展。以此带来的传感器、控制器、灵巧 手等板块的阶段性机会将会反复出现。5-6月关注机器人格斗大赛的进展。3）半导体国产化仍是大势所 趋，关注其中的半导体设备、晶圆制造、半导体材料、IC设计等。4）低空经济自24年11月宣布六大试 点城市后，建设加速的预期逐步发酵，加之春季行情启动后表现相对落后，存在较强的补涨预期。关注 地面起降场建设、低空飞行器整机等。5）创新药经历了近4年的调整后逐步迎来收获期，自2024年三季 度以来已经连续三个季度净利润增速为正，预计2025年创新药将迎来基本面拐点 ...

Group 1 - The Hong Kong stock market opened strong on May 20, with the Hong Kong Innovation Drug ETF (159570) rising over 3.6% and quickly surpassing a transaction volume of 4 billion [1] - The Hong Kong Innovation Drug ETF has seen a net inflow of over 2.2 billion in the last 60 days, indicating strong investor interest in the innovative drug sector [1] - On May 20, 2023, 3SBio announced a partnership with Pfizer, granting exclusive rights for the global development, production, and commercialization of its proprietary PD-1/VEGF bispecific antibody SSGJ-707 outside of mainland China [1] Group 2 - According to the agreement, 3SBio will receive a non-refundable upfront payment of $1.25 billion and up to $4.8 billion in milestone payments related to development, regulatory approval, and sales [1] - 3SBio will also receive a tiered sales royalty based on product sales in the licensed territories, and Pfizer will purchase $100 million worth of common stock in 3SBio upon the agreement's effective date [1] - The majority of the popular component stocks in the Hong Kong Innovation Drug ETF saw gains, with 3SBio rising over 30% [3] Group 3 - The 2025 ASCO Annual Meeting, recognized as a major oncology conference, will take place from May 30 to June 3, 2025, in Chicago, Illinois [3] - Several innovative drug companies are expected to disclose significant data at the ASCO meeting, with 3SBio set to present Phase 2 data for SSGJ-707 in non-small cell lung cancer [3] - The recent U.S. drug price reduction executive order may lead to global pharmaceutical companies adjusting their pricing strategies, with China's innovative drugs potentially becoming a preferred choice for business development transactions [4][5] Group 4 - The U.S. executive order aims to provide the best price for prescription drugs, but its short-term impact on innovative drug prices is expected to be limited due to the lack of implementation details and potential legal challenges [5] - Long-term pressures on U.S. drug prices are anticipated as Medicare and Medicaid expenditures are projected to grow from $1.5 trillion to $2.0 trillion from 2020 to 2024, with an annual growth rate of 7.0% [5] - The Hong Kong Innovation Drug ETF (159570) has a high concentration in innovative drugs, with over 85% of its weight in innovative drug stocks, making it a prominent player in the market [6]

拐点已现，积极配置 ——CXO 2024&2025Q1业绩综述 行业评级：看好 2025年05月14日 | 分析师 | 郭双喜 | 王帅 | | --- | --- | --- | | 邮箱 | guoshuangxi@stocke.com.cn | wangshuai@stocke.com.cn | | 电话 | 19801116960 | 13548094491 | | 证书编号 | S1230521110002 | S1230523060003 | 1 1、股价复盘： 2、财务分析： ➢ 本土：业绩、订单&AI是主线。 2024.12.31至2025.04.30，医疗研发外包指数上涨0.82%，跑赢医药生物（申 万）指数0.64pct，其中药明生物（+31.55%） 、药明合联（+23.65%） 、泓博医药（+16.11%） 、凯莱英 （+7.77%）、药明康德（+7.50%）表现较好。 95% ➢ 海外：业绩分化，CDMO更强劲。2024.12.31至2025.04.30，Lonza及LABCORP领涨。从指引看跨国CXO公 司只有Lonza对CDMO业务（胶囊与健康原料CHI以外业务）2025年指引 ...

Group 1 - The Hong Kong stock market opened lower on May 19, with the Hang Seng Index down 0.73% and the Hang Seng Tech Index down 1.58% [1] - The Hong Kong Innovative Drug ETF (159567) rose by 0.58% with a turnover rate of 8.02% and a trading volume exceeding 1.15 billion yuan, indicating active trading [1] - The innovative drug ETF closely tracks the Hong Kong Stock Connect Innovative Drug Index, reflecting the performance characteristics of biotech companies listed in Hong Kong [1] Group 2 - The pharmaceutical sector has shown a strong rebound this year, with several pharmaceutical funds reporting net value increases exceeding 30% [1] - Institutions are focusing on investment opportunities in AI healthcare, brain-computer interfaces, and innovative drugs following a period of deep adjustment in the pharmaceutical sector [1] - Guojin Securities emphasizes that innovative drugs and certain semi-innovative drugs remain key investment areas, with upcoming policy changes and data releases expected to catalyze stock price movements [1] Group 3 - Guoxin Securities highlights the rapid growth phase of the innovative drug sector, driven by commercialization and external licensing, which is accelerating revenue growth and profitability [2] - The traditional Chinese medicine sector faces short-term pressure but retains long-term branding and innovation potential [2] - The medical device sector is under short-term pressure due to slow policy implementation and inventory issues, but there are expectations for recovery driven by improved bidding processes [2]

以下文章来源于申万宏源策略 ，作者申万宏源策略 申万宏源策略 . 所以，主动公募向业绩比较基准靠拢，符合海外经验，可能是A股市场和公募行业发展的最终 状态。短期，市场博弈公募持仓向业绩比较基准靠拢，更偏向于是资金博弈主题，需严守性价 比，把握好节奏。 短期宏观预期难有方向性变化，行业结构也缺乏突破方向，我们维持二季度是中枢偏高震荡市 的判断。中美日内瓦经贸联合声明后，中国外需预期修复，支持A股向上挑战震荡区间上限。 但2025年供给增速中枢仍偏高，2025年内A股供需格局难有向上拐点的预期不变。中期A股基 本面节奏预期并未根本变化，暂不足以支持A股向上突破。 同时，二季度经济基本面有望脉冲式改善。中美经贸关系缓和，二季度从"抢转口"到"抢出 口"，外需从初步显现下行压力，到可能脉冲式上行。尽管基本面改善尚无法外推，但短期数 据验证有望保持强势，至少排除了下行风险。5月政策兑现成为主要矛盾阶段，宽货币及时全 面兑现。平准基金有力支撑资本市场预期，A股市场下行风险同样可控。 结构上，科技、消费、医药是A股一季报高景气的主要方向。二季度外需脉冲式改善，政策对 冲受益的消费短期基本面弹性受限。科技需要新产业趋势催化， ...

Investment Rating - The report indicates a positive outlook for the pharmaceutical and biotechnology industry, suggesting it is at a turning point for profit improvement and has high allocation value [3][4]. Core Insights - The pharmaceutical sector is showing signs of recovery after three years of declining profitability, with a notable increase in net profit margin by 0.3% in Q1 2025 compared to the previous year [3][5]. - Key sub-sectors such as CXO, innovative drugs, biological products, private hospitals, and medical consumables have demonstrated strong performance in Q1 2025, with several leading companies exceeding expectations [3][4]. - The report recommends focusing on sub-sectors and companies with clear upward trends in performance, including innovative drugs and CXO services [3][4]. Overall Performance of the Sector - In 2024, 473 A-share pharmaceutical companies achieved total revenue of 24,588 billion yuan, a year-on-year decrease of 0.9%, and a net profit of 1,412 billion yuan, down 12.1% [3][5]. - For Q1 2025, the sector reported revenue of 6,104 billion yuan, a decline of 4.2% year-on-year, with net profit at 487 billion yuan, down 8.7% [3][5]. Sub-sector Performance - The CXO sector has shown a turnaround since Q4 2024, with Q1 2025 revenue of 225 billion yuan, reflecting an 11.6% year-on-year increase, and net profit of 50 billion yuan, up 72.8% [3][23]. - The innovative drug sector continues to grow rapidly, with leading companies like Heng Rui Medicine and Bai Jie Shen Zhou performing above expectations [3][18]. - The hospital sector is beginning to show signs of recovery, with Q1 2025 revenue of 144 billion yuan, a year-on-year increase of 4.9%, and net profit of 11 billion yuan, up 19.2% [3][28]. Investment Analysis - The report emphasizes the importance of investing in sectors and companies that are showing clear signs of upward trends, particularly in innovative drugs and CXO services [3][4]. - Specific companies recommended for investment include Heng Rui Medicine, Bai Jie Shen Zhou, and Wu Xi AppTec in the innovative drug and CXO sectors [3][4].

泰格医药营收同比下降超10%，归母净利润、扣非净利润分别下滑79.99%、42.13%，均创下历史最大跌 幅。主因临床订单价格战挤压利润空间，临床试验技术服务板块的毛利率从38.21%降至29.56%，降幅 高达8.65个百分点。同时 ，公司持有的君实生物、信达生物等Biotech股权二级市场估值缩水导致全年 非经常性损益亏损4.5亿元。 博腾股份更是由盈转亏，历史首次出现年度亏损，当期归母净利润、扣非净利润分别为-2.88亿 元、-2.72亿元。由于博腾股份九成收入来自小分子业务，在新兴赛道布局滞后，因而成为利润下滑幅 度最大的厂商之一。 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 2024年，CXO赛道企业业绩显著承压，20家CXO企业实现营业收入870亿元，同比下滑4.3%；归母净利 润133.3亿元，同比下降23.9%；扣非净利润132.4亿元，降幅20.1%。从企业角度看，药明康德、康龙化 成、泰格医药、凯莱英、博腾股份五大头部企业净利润全线下滑。 其中，药明康德营收、净利润分别同比下滑2.73%、1.37%，历史首次出现营收、利润双降；康龙化成 归母净利润虽同比增长1 ...